{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:15:26Z","timestamp":1790936126885,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s12020-021-02644-x","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T03:46:30Z","timestamp":1612928790000},"page":"31-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors"],"prefix":"10.1007","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5013-657X","authenticated-orcid":false,"given":"Mei","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0374-2539","authenticated-orcid":false,"given":"Liang-Liang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Lin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9345-0825","authenticated-orcid":false,"given":"Shu-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"issue":"15","key":"2644_CR1","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"C.P. Cannon, R. Pratley, S. Dagogo-Jack et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 383(15), 1425\u20131435 (2020)","journal-title":"N Engl J Med"},{"issue":"24","key":"2644_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"V. Perkovic, M.J. Jardine, B. Neal et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24), 2295\u20132306 (2019)","journal-title":"N Engl J Med"},{"issue":"4","key":"2644_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"S.D. Wiviott, I. Raz, M.P. Bonaca et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4), 347\u2013357 (2019)","journal-title":"N Engl J Med"},{"issue":"7","key":"2644_CR4","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"B. Neal, V. Perkovic, K.W. Mahaffey et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7), 644\u2013657 (2017)","journal-title":"N Engl J Med"},{"issue":"22","key":"2644_CR5","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"B. Zinman, C. Wanner, J.M. Lachin et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22), 2117\u20132128 (2015)","journal-title":"N Engl J Med"},{"issue":"15","key":"2644_CR6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"M. Packer, S.D. Anker, J. Butler et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15), 1413\u20131424 (2020)","journal-title":"N Engl J Med"},{"issue":"21","key":"2644_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"J McMurray","year":"2019","unstructured":"J. McMurray, S.D. Solomon, S.E. Inzucchi et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21), 1995\u20132008 (2019)","journal-title":"N Engl J Med"},{"issue":"15","key":"2644_CR8","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"H Heerspink","year":"2020","unstructured":"H. Heerspink, B.V. Stef\u00e1nsson, R. Correa-Rotter et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15), 1436\u20131446 (2020)","journal-title":"N Engl J Med"},{"issue":"1","key":"2644_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41387-019-0098-5","volume":"9","author":"Y Tang","year":"2019","unstructured":"Y. Tang, Q. Sun, X.Y. Bai, Y.F. Zhou, Q.L. Zhou, M. Zhang, Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study. NUTR DIABETES 9(1), 32 (2019)","journal-title":"NUTR DIABETES"},{"issue":"9","key":"2644_CR10","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1507\/endocrj.EJ17-0545","volume":"65","author":"S Furukawa","year":"2018","unstructured":"S. Furukawa, T. Miyake, H. Senba et al. The effectiveness of dapagliflozin for sleep-disordered breathing among japanese patients with obesity and type 2 diabetes mellitus. ENDOCR J 65(9), 953\u2013961 (2018)","journal-title":"ENDOCR J"},{"issue":"4","key":"2644_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1507\/endocrj.EJ17-0440","volume":"65","author":"K Sawada","year":"2018","unstructured":"K. Sawada, S. Karashima, M. Kometani et al. Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes. ENDOCR J 65(4), 461\u2013467 (2018)","journal-title":"ENDOCR J"},{"issue":"7","key":"2644_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the prisma statement. PLOS Med 6(7), e1000097 (2009)","journal-title":"PLOS Med"},{"key":"2644_CR13","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"J.P. Higgins, D.G. Altman, P.C. Gotzsche et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011)","journal-title":"BMJ"},{"issue":"7414","key":"2644_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G.A. Measuring, inconsistency in meta-analyses. BMJ 327(7414), 557\u2013560 (2003)","journal-title":"BMJ"},{"issue":"11","key":"2644_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"J.P. Higgins, S.G. Thompson, Quantifying heterogeneity in a meta-analysis. Stat Med 21(11), 1539\u20131558 (2002)","journal-title":"Stat Med"},{"key":"2644_CR16","doi-asserted-by":"publisher","first-page":"109631","DOI":"10.1016\/j.mehy.2020.109631","volume":"139","author":"S Brikman","year":"2020","unstructured":"S. Brikman, G. Dori, Sodium glucose cotransporter2 inhibitor-possible treatment for patients with diabetes, pulmonary disease and co(2) retention. Med Hypotheses 139, 109631 (2020)","journal-title":"Med Hypotheses"},{"issue":"1","key":"2644_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bbrc.2020.01.015","volume":"524","author":"B Chowdhury","year":"2020","unstructured":"B. Chowdhury, A.Z. Luu, V.Z. Luu et al. The sglt2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension. Biochem Biophys Res Commun 524(1), 50\u201356 (2020)","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2644_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51648-1","volume":"9","author":"HJ Park","year":"2019","unstructured":"H.J. Park, H. Han, E.Y. Oh et al. Empagliflozin and dulaglutide are effective against obesity-induced airway hyperresponsiveness and fibrosis in a murine model. Sci Rep 9(1), 15601 (2019)","journal-title":"Sci Rep"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02644-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02644-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02644-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T17:23:50Z","timestamp":1623950630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02644-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["2644"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02644-x","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"7 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}